Product Description
Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a617016.html)
Mechanisms of Action: ALK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: Lymphoma | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified
Known Adverse Events: Headache | Diarrhea
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Brazil, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Mexico, Netherlands, Poland, Romania, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
Active Clinical Trial Count: 15
Highest Development Phases
Phase 3: Lymphoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Breast Cancer|Ependymoma|Granuloma|Intestinal Cancer|Large-Cell Anaplastic Lymphoma|Meningioma|Neurilemmoma|Neurofibromatoses|Neurofibromatosis 1|Neurofibromatosis 2|Neuroma, Acoustic|Squamous Cell Carcinoma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BrigaPED | P2 |
Active, not recruiting |
Lymphoma |
2031-06-30 |
|
| Briga-PED | P2 |
Recruiting |
Granuloma|Large-Cell Anaplastic Lymphoma |
2029-12-01 |
|
| INTUITT-NF2 | P2 |
Recruiting |
Neurilemmoma|Meningioma|Neurofibromatoses|Neurofibromatosis 2|Neuroma, Acoustic|Ependymoma|Neurofibromatosis 1 |
2029-12-01 |
|
| BOUNCE | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2027-04-01 |